Literature DB >> 26968553

c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.

Xinyu Ren1, Li Yuan1, Songjie Shen2, Hanwen Wu1, Junliang Lu1, Zhiyong Liang3.   

Abstract

Basal-like breast cancer (BLBC) and triple-negative breast cancer (TNBC) are two entities of breast cancer that share similar poor prognosis. Even though both cancers have overlaps, there are still some differences between those two types. It has been reported that the c-Met high expression was associated with poor prognosis not only in breast cancer but also in many other cancers. The role of ERβ in pathogenesis and treatment of breast cancer has remained controversial. In this study, we firstly distinguished basal-like from nonbasal-like cancer patients in TNBC patients using CK5/6 and EGFR as markers and next determined the relationship of basal-like breast cancer with c-Met or ERβ expression levels and prognosis in TNBC patients. One hundred twenty-seven patients who had been diagnosed with TNBC were enrolled. The clinical and pathological characteristics of the patients were recorded. The expression of EGFR, CK5/6, ERβ, and c-Met were evaluated with immunohistochemical methods using paraffin blocks. The median age of patients was 50.7 years. CK5/6 immunopositivity was 31.5 % (40/127), and EGFR was 40.2 % (51/127). Of the TNBC cases, 55.1 % (71/127) were positive for either CK5/6 or EGFR and were thus classified as basal-like breast cancer. C-Met (P < 0.001) and ERβ (P = 0.002) overexpression, small tumor sizes, a ductal subtype, and high-grade tumor were significantly correlated with BLBC. High c-Met expression was detected in 43.3 % patients. Metastatic lymph nodes and tumor size (>5 cm), which were both important prognostic predictors, were significantly associated with recurrence and mortality. BLBC typically demonstrates a unique profile. CK5/6 and EGFR expression combination indicates a higher basal-like phenotype possibility. The expression of c-Met and ERβ were significantly related to the basal-like phenotype. The classical markers, lymph node metastasis, and tumor size were found to have important prognostic value. However, high c-Met expression and basal-like phenotypes did not show a direct correlation with poor prognosis.

Entities:  

Keywords:  Basal-like breast cancer; CK5/6; EGFR; ERβ; Triple-negative breast cancer; c-Met

Mesh:

Substances:

Year:  2016        PMID: 26968553     DOI: 10.1007/s13277-016-5010-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  35 in total

1.  Gene expression profiling of breast cell lines identifies potential new basal markers.

Authors:  E Charafe-Jauffret; C Ginestier; F Monville; P Finetti; J Adélaïde; N Cervera; S Fekairi; L Xerri; J Jacquemier; D Birnbaum; F Bertucci
Journal:  Oncogene       Date:  2006-04-06       Impact factor: 9.867

2.  Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers.

Authors:  F-C Bidard; R Conforti; T Boulet; S Michiels; S Delaloge; F André
Journal:  Ann Oncol       Date:  2007-07       Impact factor: 32.976

3.  Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

Authors:  Carrie R Graveel; Jack D DeGroot; Yanli Su; Julie Koeman; Karl Dykema; Samuel Leung; Jacqueline Snider; Sherri R Davies; Pamela J Swiatek; Sandra Cottingham; Mark A Watson; Matthew J Ellis; Robert E Sigler; Kyle A Furge; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-30       Impact factor: 11.205

4.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.

Authors:  Chad A Livasy; Gamze Karaca; Rita Nanda; Maria S Tretiakova; Olufunmilayo I Olopade; Dominic T Moore; Charles M Perou
Journal:  Mod Pathol       Date:  2006-02       Impact factor: 7.842

Review 5.  Estrogen receptors in breast carcinogenesis and endocrine therapy.

Authors:  Bo Huang; Margaret Warner; Jan-Åke Gustafsson
Journal:  Mol Cell Endocrinol       Date:  2014-11-26       Impact factor: 4.102

6.  Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer.

Authors:  Mevlude Inanc; Metin Ozkan; Halit Karaca; Veli Berk; Oktay Bozkurt; Ayse Ocak Duran; Ersin Ozaslan; Hulya Akgun; Fatos Tekelioglu; Ferhan Elmali
Journal:  Med Oncol       Date:  2013-12-11       Impact factor: 3.064

7.  Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.

Authors:  Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

8.  Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.

Authors:  David S P Tan; Caterina Marchió; Robin L Jones; Kay Savage; Ian E Smith; Mitch Dowsett; Jorge S Reis-Filho
Journal:  Breast Cancer Res Treat       Date:  2007-10-06       Impact factor: 4.872

9.  C-Met in invasive breast cancer: is there a relationship with the basal-like subtype?

Authors:  Colan M Ho-Yen; Andrew R Green; Emad A Rakha; Adam R Brentnall; Ian O Ellis; Stephanie Kermorgant; J L Jones
Journal:  Cancer       Date:  2013-10-21       Impact factor: 6.860

10.  Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.

Authors:  Yi Du; Hirohito Yamaguchi; Yongkun Wei; Jennifer L Hsu; Hung-Ling Wang; Yi-Hsin Hsu; Wan-Chi Lin; Wen-Hsuan Yu; Paul G Leonard; Gilbert R Lee; Mei-Kuang Chen; Katsuya Nakai; Ming-Chuan Hsu; Chun-Te Chen; Ye Sun; Yun Wu; Wei-Chao Chang; Wen-Chien Huang; Chien-Liang Liu; Yuan-Ching Chang; Chung-Hsuan Chen; Morag Park; Philip Jones; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Nat Med       Date:  2016-01-18       Impact factor: 53.440

View more
  5 in total

1.  PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.

Authors:  Xinyu Ren; Huanwen Wu; Junliang Lu; Yuhan Zhang; Yufeng Luo; Qianqian Xu; Songjie Shen; Zhiyong Liang
Journal:  Cancer Biol Ther       Date:  2018-02-16       Impact factor: 4.742

2.  Clinicopathological and prognostic significance of c-Met overexpression in breast cancer.

Authors:  Xixi Zhao; Jingkun Qu; Yuxin Hui; Hong Zhang; Yuchen Sun; Xu Liu; Xiaoyao Zhao; Zitong Zhao; Qian Yang; Feidi Wang; Shuqun Zhang
Journal:  Oncotarget       Date:  2017-05-24

3.  Association between miR-199a rs74723057 and MET rs1621 polymorphisms and the risk of hepatocellular carcinoma.

Authors:  Qianqian Wang; Xiangyuan Yu; Qiang Li; Linyuan Qin; Shengkui Tan; Xiaoyun Zeng; Xiaoqiang Qiu; Bo Tang; Junfei Jin; Weijia Liao; Moqin Qiu; Lijun Tan; Gaofeng He; Xiaomei Li; Songqing He; Hongping Yu
Journal:  Oncotarget       Date:  2016-11-29

4.  VISTA Expression on Immune Cells Correlates With Favorable Prognosis in Patients With Triple-Negative Breast Cancer.

Authors:  Xi Cao; Xinyu Ren; Yidong Zhou; Feng Mao; Yan Lin; Huanwen Wu; Qiang Sun
Journal:  Front Oncol       Date:  2021-01-11       Impact factor: 6.244

5.  MET and FASN as Prognostic Biomarkers of Triple Negative Breast Cancer: A Systematic Evidence Landscape of Clinical Study.

Authors:  Weihua Jiang; Xiao-Liang Xing; Chenguang Zhang; Lina Yi; Wenting Xu; Jianghua Ou; Ning Zhu
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.